{"id":"NCT01005901","sponsor":"Novartis","briefTitle":"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo","officialTitle":"A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2009-11-02","resultsPosted":"2012-04-12","lastUpdate":"2012-04-12"},"enrollment":1324,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Glycopyrronium bromide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Glycopyrronium bromide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks","timeFrame":"12 weeks","effectByArm":[{"arm":"Glycopyrronium Bromide","deltaMin":1.408,"sd":0.0105},{"arm":"Placebo","deltaMin":1.301,"sd":0.0137}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":96,"countries":["United States","Australia","Canada","Japan","Netherlands","Romania","Russia","Singapore","South Korea","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["22151296","24156566"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":550},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection"]}}